Close

TG Therapeutics (TGTX) Launches Phase 1/2 Study of TGR-1202 and Carfilzomib in Relapsed or Refractory Lymphoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. NFLX
2. TSM
3. ISRG
4. TSLA
5. SPY
6. INFY
7. SNV
8. SMCI
9. SLB
10. PPG


Go back to TG Therapeutics (TGTX) Launches Phase 1/2 Study of TGR-1202 and Carfilzomib in Relapsed or Refractory Lymphoma
TG THERAP (NASDAQ: TGTX) Delayed: 13.78 -0.21 (1.5%)
Previous Close $13.99    52 Week High $14.87 
Open $13.87    52 Week Low $4.90 
Day High $14.02    P/E N/A 
Day Low $13.26    EPS $-0.67 
Volume 3,665,965